Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 14, 2025

BUY
$3.79 - $6.65 $6,822 - $11,970
1,800 Added 8.0%
24,300 $92,000
Q4 2024

Feb 14, 2025

BUY
$4.01 - $5.45 $90,225 - $122,625
22,500 New
22,500 $119,000

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $183M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Omers Administration Corp Portfolio

Follow Omers Administration Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Omers Administration Corp, based on Form 13F filings with the SEC.

News

Stay updated on Omers Administration Corp with notifications on news.